Reprinted from *WHO Chronicle*, Vol. 21, No. 11, pp. 478-502

INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 18

International Non-Proprietary Names for Pharmaceutical Preparations

In accordance with article 3 of the Procedure for the Selection of Recommended International Non-Proprietary Names for Pharmaceutical Preparations,[1] notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Non-Proprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by an person to the Pharmaceuticals unit of th World Health Organization within four months of the date of their publication in the *WHO Chronicle*.

The inclusion of a name in the lists of proposed international non-proprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 18 [2]

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
acetergaminum acetergamine	(+)-*N*-acetyl-9,10-dihydrolysergamine $C_{17}H_{21}N_3O$
	
acidum acexamicum acexamic acid	6-acetamidohexanoic acid $C_8H_{15}NO_3$
	$H_3C-CO-NH-CH_2-CH_2-CH_2-CH_2-CH_2-COOH$

[1] See Annex, p. 500.

[2] Other lists of proposed international non-proprietary names can be found in *Chron. Wld Hlth Org.*, 1953, 7, 299; 1954, 8, 216, 313; 1956, 10, 28; 1957, 11, 231; 1958, 12, 102; *WHO Chronicle*, 1959, 13, 105, 152; 1960, 14, 168, 244; 1961, 15, 314; 1962, 16, 385; 1963, 17, 389; 1964, 18, 433; 1965, 19, 446; 1966, 20, 216; 1967, 21, 70.

Lists of recommended international non-proprietary names were published in *Chron. Wld Hlth Org.*, 1955, 9, 185; *WHO Chronicle*, 1959, 13, 106, 463; 1962, 16, 101; 1965, 19, 165, 206, 249; 1966, 20, 421.

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
acidum amfonelicum amfonelic acid	7-benzyl-1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid $C_{18}H_{18}N_2O_3$ 
acidum cromoglicicum cromoglicic acid	5,5′-(2-hydroxytrimethylenedioxy)bis[4-oxo-4*H*-1-benzopyran-2-carboxylic acid] $C_{23}H_{16}O_{11}$ 
acidum cyclobutoicum cyclobutoic acid	*β*-hydroxy-*β*-methylcyclohexanepropionic acid $C_{10}H_{18}O_3$ 
acidum iocetamicum iocetamic acid	*N*-acetyl-*N*-(3-amino-2,4,6-triiodophenyl)-2-methyl-*β*-alanine $C_{12}H_{13}I_3N_2O_3$ 
alipamidum alipamide	4-chloro-3-sulfamoylbenzoic acid 2,2-dimethylhydrazide $C_9H_{12}ClN_3O_3S$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
amiloridum amiloride	*N*-amidino-3,5-diamino-6-chloropyrazinecarboxamide $C_6H_8ClN_7O$ 
azaperonum azaperone	4'-fluoro-4-[4-(2-pyridyl)-1-piperazinyl]butyrophenone $C_{19}H_{22}FN_3O$ 
azatadinum azatadine	6,11-dihydro-11-(1-methyl-4-piperidylidene)-5*H*-benzo[5,6]cyclohepta-[1,2-*b*]pyridine $C_{20}H_{22}N_2$ 
benazolinum benazoline	2-[(2-methylbenzo[*b*]thien-3-yl)methyl]-2-imidazoline $C_{13}H_{14}N_2S$ 
bensalanum bensalan	3,5-dibromo-*N*-(*p*-bromobenzyl)salicylamide $C_{14}H_{10}Br_3NO_2$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
bentipiminum bentipimine	1-[2-[(*o*-chloro-α-phenylbenzyl)thio]ethyl]-4-(*o*-methylbenzyl)piperazine $C_{27}H_{31}ClN_2S$
	
benzathini benzylpenicillinum benzathine benzylpenicillin	*N,N'*-dibenzylethylenediamine salt of benzylpenicillin $C_{16}H_{20}N_2 \cdot 2C_{16}H_{18}N_2O_4S$
	
benzoxiquinum benzoxiquine	8-quinolinol benzoate (ester) $C_{16}H_{11}NO_2$
	
bisoxatinum bisoxatin	2,2-bis(*p*-hydroxyphenyl)-2*H*-1,4-benzoxazin-3(4*H*)-one $C_{20}H_{15}NO_4$
	
boxidinum boxidine	1-{2-[[4'-(trifluoromethyl)-4-biphenylyl]oxy]ethyl}pyrrolidine $C_{19}H_{20}F_3NO$
	

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
brocresinum brocresine	α-(aminooxy)-6-bromo-*m*-cresol $C_7H_6BrNO_2$ 
bromelaina bromelains	a concentrate of proteolytic enzymes derived from *Ananas comosus* Merr.
captaminum captamine	2-(dimethylamino)ethanethiol $C_4H_{11}NS$ 
cefalexinum cefalexin	D-7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid $C_{16}H_{17}N_3O_4S$ 
cellacefatum cellacefate	a mixed acetate and hydrogen phthalate ester of cellulose (about 50 per cent. of the hydroxyl groups are acetylated and about 25 per cent. are esterified with one of the carboxyl groups of phthalic acid)
ciclactatum ciclactate	3,3,5-trimethylcyclohexyl lactate $C_{12}H_{22}O_3$ 
ciclofenazinum ciclofenazine	10-[3-(4-cyclopropyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine $C_{23}H_{26}F_3N_3S$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
cinperenum cinperene	2-(1-cinnamyl-4-piperidyl)-2-phenylglutarimide $C_{23}H_{24}N_2O_2$
	
ciproximidum ciproximide	1-(*p*-chlorophenyl)-1,2-cyclopropanedicarboximide $C_{11}H_8ClNO_2$
	
cisclomifenum cisclomifene	2-[*p*-(2-chloro-*cis*-1,2-diphenylvinyl)phenoxy]triethylamine $C_{26}H_{28}ClNO$
	
clobenzorexum clobenzorex	(+)-*N*-(*o*-chlorobenzyl)-α-methylphenethylamine $C_{16}H_{18}ClN$
	
clofluperolum clofluperol	4-[4-(*p*-chloro-*m*-trifluoromethylphenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone $C_{22}H_{22}ClF_4NO_2$
	

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
clonazolinum clonazoline	2-(4-chloro-1-naphthylmethyl)-2-imidazoline $C_{14}H_{13}ClN_2$ 
cloperastinum cloperastine	1-[2-[(*p*-chloro-α-phenylbenzyl)oxy]ethyl]piperidine $C_{20}H_{24}ClNO$ 
decitropinum decitropine	3α-(5*H*-dibenzo[a,*d*]cyclohepten-5-yloxy)tropane $C_{23}H_{25}NO$ 
diaveridinum diaveridine	2,4-diamino-5(3',4'-dimethoxybenzyl)pyrimidine $C_{13}H_{16}N_4O_2$ 
diflucortolonum diflucortolone	6α,9-difluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione $C_{22}H_{28}F_2O_4$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
diniprofyllinum diniprofylline	7-(2,3-dihydroxypropyl)theophylline bis(nicotinate ester) $C_{22}H_{20}N_6O_6$ 
dopaminum dopamine	4-(2-aminoethyl)pyrocatechol $C_8H_{11}NO_2$ 
dropropizinum dropropizine	3-(4-phenyl-1-piperazinyl)-1,2-propanediol $C_{13}H_{20}N_2O_2$ 
emepronii bromidum emepronium bromide	ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide $C_{20}H_{26}BrN$ 
etamocyclinum etamocycline	*N,N*,-[ethylenebis[(methylimino)methylene]]bis[4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide] $C_{50}H_{60}N_8O_{16}$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
etilefrinum etilefrine	α-[(ethylamino)methyl]-*m*-hydroxybenzyl alcohol $C_{10}H_{15}NO_2$ 
etodroxizinum etodroxizine	2-[2-[2-[4-(*p*-chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethoxy] ethanol $C_{23}H_{31}ClN_2O_3$ 
etofuradinum etofuradine	*N*-(benzofuran-2-ylmethyl)-*N*-2-pyridyl-*N'*,*N'*-dimethylethylenediamine $C_{16}H_{21}N_3O$ 
etonamum etonam	ethyl 1-(1,2,3,4-tetrahydro-1-naphthyl)imidazole-5-carboxylate $C_{16}H_{18}N_2O_2$ 
fantridonum fantridone	5-[3-(dimethylamino)propyl]-6(5*H*)-phenanthridinone $C_{18}H_{20}N_2O$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
fenalamidum fenalamide	ethyl *N*-[2-(diethylamino)ethyl]-2-ethyl-2-phenylmalonamate $C_{18}H_{30}N_2O_3$ 
fencloninum fenclonine	3-(*p*-chlorophenyl)alanine $C_9H_{10}ClNO_2$ 
fenestrelum fenestrel	5-ethyl-6-methyl-4-phenyl-3-cyclohexene-1-carboxylic acid $C_{16}H_{20}O_2$ 
fluprofenum fluprofen	2-(3'-fluoro-4-biphenylyl)propionic acid $C_{15}H_{13}FO_2$ 
fomocainum fomocaine	1-{3-[4-(phenoxymethyl)phenyl]propyl}morpholine $C_{20}H_{25}NO_2$ 
formocortalum formocortal	3-(2-chloroethoxy)-9-fluoro-11β,16α,17,21-tetrahydroxy-20-oxo-3,5-pregnadiene-6-carboxaldehyde cyclic 16,17-acetal with acetone 21-acetate $C_{28}H_{34}ClFO_6$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
fubrogonii iodidum fubrogonium iodide	diethyl(3-hydroxybutyl)methylammonium iodide 5-bromo-2-furoate $C_{14}H_{23}BrINO_3$
	
fursalanum fursalan	3,5-dibromo-*N*-(tetrahydrofurfuryl)salicylamide $C_{12}H_{13}Br_2NO_3$
	
glibenclamidum glibenclamide	1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]phenylsulfonyl]-3-cyclohexylurea $C_{23}H_{28}ClN_3O_5S$
	
guancidinum guancidine	1-cyano-3-*tert*-pentylguanidine $C_7H_{14}N_4$
	
hypromellosum hypromellose	a mixed methyl and hydroxypropyl ether of cellulose (about 4 to 7 per cent. hydroxypropyl groups and 20 to 30 per cent. methoxyl groups)
imiclopazinum imiclopazine	1-{2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazinyl)ethyl}-3-methyl-2-imidazolidinone $C_{25}H_{32}ClN_5OS$
	

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
leniquinsinum leniquinsin	6,7-dimethoxy-4-(veratrylideneamino)quinoline $C_{20}H_{20}N_2O_4$ 
levometiomeprazinum levometiomeprazine	(−)-10-[3-(dimethylamino)-2-methylpropyl]-2-(methylthio) phenothiazine $C_{19}H_{24}N_2S_2$ 
mecarbinatum mecarbinate	ethyl 5-hydroxy-1,2-dimethylindole-3-carboxylate $C_{13}H_{15}NO_3$ 
metergolinum metergoline	(+)-*N*-(carboxy)-1-methyl-9,10-dihydrolysergamine benzyl ester $C_{25}H_{29}N_3O_2$ 
minepentatum minepentate	2-[2-(dimethylamino)ethoxy]ethyl 1-phenylcyclopentanecarboxylate $C_{18}H_{27}NO_3$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
mitoclominum mitoclomine	*N,N*-bis(2-chloroethyl)-4-methoxy-3-methyl-1-naphthylamine $C_{15}H_{19}Cl_2NO$ 
molindonum molindone	3-ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5*H*)-one $C_{14}H_{24}N_2O_2$ 
moxicoumonum moxicoumone	4-methyl-5,7-bis(2-morpholinoethoxy)coumarin $C_{22}H_{30}N_2O_6$ 
naftidrofurylum naftidrofuryl	2-(diethylamino)ethyl tetrahydro-α-(1-naphthylmethyl)-2-furanpropionate ester $C_{24}H_{33}NO_3$ 
natrii radioiotalamas (^{125}I) sodium radioiotalamate (^{125}I)	sodium 5-acetamido-*ar*,*ar*-diiodo-*ar*, iodo-^{125}I-*N*-methylisophthalamate $C_{11}H_8I_3N_2NaO_4$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
natrii radioiotalamas (^{131}I) sodium radioiotalamate (^{131}I)	sodium 5-acetamido-*ar*,*ar*-diiodo-*ar*-iodo-^{131}*I*-*N*-methylisophthalamate $C_{11}H_8I_3N_2NaO_4$
	
nifurimidum nifurimide	(±)-4-methyl-1-[(5-nitrofurfurylidene)amino]-2-imidazolidinone $C_9H_{10}N_4O_4$
	
nifurquinazolum nifurquinazol	2,2′-{[2-(5-nitro-2-furyl)-4-quinazolinyl]imino}diethanol $C_{16}H_{19}N_5O_5$
	
nonoxinolum 4 nonoxinol 4	2-{2-[2-[2-(*p*-nonylphenoxy)ethoxy]ethoxy]ethoxy}ethanol $C_{23}H_{40}O_5$
	
nonoxinolum 15 nonoxinol 15	44-(*p*-nonylphenoxy)-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradecaoxatetratetracontan-1-ol $C_{45}H_{84}O_{16}$
	
nonoxinolum 30 nonoxinol 30	89-(*p*-nonylphenoxy)-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,87-nonacosaoxanonaoctacontan-1-ol $C_{75}H_{144}O_{31}$
	

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
norgestrienonum norgestrienone	17-hydroxy-19-nor-17α-pregna-4,9,11-trien-20-yn-3-one $C_{20}H_{22}O_2$ 
norleusactidum norleusactide	D-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-propyl-L-valyl-glycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-prolyl-L-valinamide $C_{148}H_{223}N_{45}O_{31}$ 
octabenzonum octabenzone	2-hydroxy-4-(octyloxy)benzophenone $C_{21}H_{26}O_3$ 
octaverinum octaverine	6,7-dimethoxy-1-(3,4,5-triethoxyphenyl)isoquinoline $C_{23}H_{27}NO_5$ 
olivomycinum olivomycin	an antibiotic obtained from cultures of *Actinomyces olivoreticuli*, or the same substance obtained by any other means
oxipurinolum oxipurinol	1*H*-pyrazolo[3,4-*d*]pyrimidine-4,6-diol $C_5H_4N_4O_2$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
oxitefonii bromidum oxitefonium bromide	diethyl(2-hydroxyethyl)methylammonium bromide α-phenyl-2-thiopheneglycolate $C_{19}H_{28}BrNO_3S$
	
parapropamolum parapropamol	4'-hydroxypropionanilid $C_9H_{11}NO_2$
	
pentagastrinum pentagastrin	*N*-t-butyloxycarbonyl-β-alanyl-L-tryptophyl-L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalanine amide $C_{37}H_{49}N_7O_9S$
	
perimetazinum perimetazine	1-[3-(2-methoxyphenothiazin-10-yl)-2-methylpropyl]-4-piperidinol $C_{22}H_{28}N_2O_2S$
	

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
picodralazinum picodralazine	1-hydrazino-4-(4-pyridylmethyl)phthalazine $C_{14}H_{13}N_5$ 
pimozidum pimozide	1-{1-[4,4-bis(*p*-fluorophenyl)butyl]-4-piperidyl}-2-benzimidazolinone $C_{28}H_{29}F_2N_3O$ 
pinoxepinum pinoxepin	*c s*-4-[3-(2-chlorodibenz[*b*,*e*]oxepin-11(6*H*)-ylidene)propyl]-1-piperazineethanol $C_{23}H_{25}ClN_2O_2$ 
piridoxilatum piridoxilate	[(5-hydroxy-4-hydroxymethyl-6-methyl-3-pyridyl)methoxy]-glycolic acid $C_{10}H_{13}NO_6$ 
polisaponinum polisaponin	a mixture of all the steroid saponins isolated from the rhizome of *Dioscorea polystachya*

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
quatacainum quatacaine	2-methyl-2-(propylamino)-*o*-propionotoluidide $C_{14}H_{22}N_2O$
	
radiocesii chloridum (^{131}Cs) radiocesium chloride (^{131}Cs)	cesium chloride $^{131}CsCl$
retinolum retinol	3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol $C_{20}H_{30}O$
	
ribaminolum ribaminol	2-diethylammonium ethanol ribonucleate
ronidazolum ronidazole	(1-methyl-5-nitroimidazol-2-yl)methyl carbamate $C_6H_8N_4O_4$
	
silandronum silandrone	17β-(trimethylsiloxy)androst-4-en-3-one $C_{22}H_{36}O_2Si$
	
sotalolum sotalol	4'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide $C_{12}H_{20}N_2O_3S$
	

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulas*
stanozololum stanozolol	17β-hydroxy-17α-methylandrostano[3,2-*c*]pyrazole $C_{21}H_{32}N_2O$ 
sulfapyrazolum sulfapyrazole	*N*¹-(3-methyl-1-phenylpyrazol-5-yl)sulfanilamide $C_{16}H_{16}N_4O_2S$ 
sulforidazinum sulforidazine	10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfonylphenothiazine $C_{21}H_{26}N_2O_2S_2$ 
sulpiridum sulpiride	*N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfamoylbenzamide $C_{15}H_{23}N_3O_4S$ 
sultroponium sultroponium	8-(3-sulfopropyl)atropinium hydroxide inner salt $C_{20}H_{29}NO_4S$ 
sutilaina sutilains	proteolytic enzymes derived from *Bacillus subtilis*

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
talastinum talastine	2-[2-(dimethylamino)ethyl]-4-benzyl-1(2*H*)phthalazinone $C_{19}H_{21}N_3O$ 
tetracosactidum tetracosactide	L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-prolyl-L-valyl-glycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-proline $C_{136}H_{210}N_{40}O_{31}S$ 
tetradonii bromidum tetradonium bromide	trimethyltetradecylammonium bromide $C_{17}H_{38}BrN$ 
tibrofanum tibrofan	4,4',5-tribromo-2-thiophenecarboxanilide $C_{11}H_6Br_3NOS$ 
tiosalanum tiosalan	3,4',5-tribromo-2-mercaptobenzanilide $C_{13}H_8Br_3NOS$ 

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae*
tixadilum tixadil	*N*-(α-methylphenethyl)thioxanthene-9-ethylamine $C_{24}H_{25}NS$



transclomifenum transclomifene	2-[*p*-(2-chloro-*trans*-1,2-diphenylvinyl)phenoxy]triethylamine $C_{26}H_{28}ClNO$



tropodifenum tropodifene	tropine 3-(*p*-hydroxyphenyl-2-phenylpropionate (ester) acetate (ester) $C_{25}H_{29}NO_4$



vanitiolidum vanitiolide	4-(thiovanilloyl)morpholine $C_{12}H_{15}NO_3S$



zolaminum zolamine	2-{[-(dimethylamino)ethyl](*p*-methoxybenzyl)amino}thiazole $C_{15}H_{21}N_3OS$



NAMES FOR RADICALS AND GROUPS

Some preparations for which a proposed international non-proprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. The following shorter non-proprietary names for some such radicals and groups have been devised or selected, and they are suggested for use with proposed international non-proprietary names.

methylphenylmethylene	acetofenide
isopropylidene ether of a dihydric alcohol	acetonide
4,4′-diaminostilbene-2,2′-disulfonate	amsonate
camphorsulfonate	camsilate
cyclopentanepropionate	cipionate
p-chlorbenzenesulfonate	closilate
1,2-ethanedisulfonate	edisilate
4,4′-methylenebis(3-hydroxy-2-naphthoate)	embonate
heptanoate	enantate
ethanesulfonate	esilate
glucoheptonate	gluceptate
o-(4-hydroxybenzoyl)benzoate	hibenzate
2-hydroxyethanesulfonate	isetionate
N-methylglucamine	meglumine
methanesulfonate	mesilate
methylsulfate	metilsulfate
1,5-naphthalenedisulfonate	napadisilate
2-naphthalenesulfonate	napsilate
trimethylacetate	pivalate
stearoyl-glycolate	steaglate
8-chlorotheophyllinate	teoclate
p-toluenesulfonate	tosilate
2,4,5-trichlorophenolate	triclofenate

CORRIGENDA

Vol. 16, No. 10

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 12

p. 390: *delete*	*insert*
meractinomycinum	dactinomycinum
meractinomycin	dactinomycin

Vol. 17, No. 10

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 13

p. 398: *delete*	*insert*
virgimycinum	virginiamycinum
virgimycin	virginiamycin

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 17

p. 71: *delete*	*insert*
antridonil chloridum antridonium chloride	isometamidii chloridum isometamidium chloride
delete	*insert*
cinnopropazonum cinnopropazone	azapropazonum azapropazone
p. 76: *delete*	*insert*
nonoxynolum nonoxynol	nonoxinolum 9 nonoxinol 9

Annex

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS *

The following procedure shall be followed by the World Health Organization in the selection of recommended international non-proprietary names for pharmaceutical preparations, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international non-proprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the " General principles for guidance in devising International Non-proprietary Names ", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical preparation shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international non-proprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*[1] and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

(i) set forth the name under consideration;

(ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;

(iii) identify the substance for which a name is being considered;

(iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

(v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3).

[1] The title of this publication was changed to *WHO Chronicle* in January 1959.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

A. Such objection shall:

(i) identify the person objecting;

(ii) state his interest in the name;

(iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international non-proprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international non-proprietary name.

8. In forwarding a recommended international non-proprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the non-proprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS *

1. Names should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names already in common use.

2. The name for a substance belonging to a group of pharmacologically related substances should show this relationship. The name should be free from any anatomical, physiological, pathological or therapeutic suggestion.

The above primary principles are to be implemented by utilization of the following secondary principles.

3. In devising the name of the first substance in a new pharmacological group (the parent substance), consideration should be given to the possibility of devising suitable names for related substances belonging to the new group.

4. Syllables such as " methylhydro ", " methoxy ", and " chlor " should preferably be abbreviated (to " medro ", " meto ", " clo ", etc.).

5. In the naming of substances which are acids, existing names generally used in chemistry which include the word " acidum " (" acid ") should be used, if the name is adequate for practical use in therapy and pharmacy. In other circumstances, the substance should be named by a single word and not by a name which includes the word " acid ". Where the word " acid " is not used in the name, as is customary in the penicillin series, a salt should preferably be named without modification of the parent acid name, e.g., " oxacillin " and " oxacillin sodium ".

6. Names for substances which are used as salts should in general apply to the active base (or the active acid). Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid (or the inactive base). Exceptions may have to be made for those cases in which pharmacological activity may reside in both parts of the salt or ester.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

* Text adopted by the Executive Board of WHO in resolution EB37.R9 (*Off. Rec. Wld Hlth Org.*, 1966, 148, 9).

7. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

8. To facilitate translation and pronunciation " f " should preferably be used instead of " ph ", " t " instead of " th ", " e " instead of " ae " or " oe ", and " i " instead of " y ".

9. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

10. Group relationship in names (see item 2) should preferably be shown by using common syllables in the following list. Where a syllable or a group of syllables is shown without any hyphens it may be used anywhere in the name. The syllable, or group of syllables, should, if possible, be used only for such substances.

Subsidiary group relationships should be shown by devising names which show similarities to and are analogous with a previously named substance, the parent substance.

At the end of the list are general chemical syllables. Should they come into conflict with other suggested syllables, the suffix conveying the best information should be used.

Latin	*English*	*French*	
-andr- or -stan- or -ster-	-andr- or -stan- or -ster-	-andr- or -stan- or -ster-	steroids, androgenic
-apol-	-apol-	-apol-	polysulfonic anticoagulants
-arolum	-arol	-arol	anticoagulants
-bamatum	-bamate	-bamate	tranquillizers of the propanediol and pentanediol series
barb	barb	barb	barbituric acids
bol	bol	bol	anabolic steroids
-cainum	-caine	-caïne	local anaesthetics
cef-	cef-	céf-	antibiotics with cefalosporanic acid nucleus
-cillinum	-cillin	-cilline	penicillins: derivatives of carboxy-6-amino-penicillanic acid
-cort-	-cort-	-cort-	steroids, glucocorticoids and mineralocorticoids, other than prednisolone derivatives
-crinum	-crine	-crine	acridine derivatives, antimicrobial
-curonium	-curonium	-curonium	curare-like drugs
-cyclinum	-cycline	-cycline	antibiotics, tetracycline derivatives
-dionum	-dione	-dione	antiepileptics derived from oxazolidinedione
-estr-	-estr-	-estr-	estrogenic drugs
-gest-	-gest-	-gest-	steroids, progestative
gli-	gli-	gli-	sulfonamide oral antidiabetics
io-	io-	io-	iodine-containing contrast media
-mer-	-mer-	-mer-	mercury-containing drugs, antimicrobial or diuretic
mito-	mito-	mito-	nucleotoxic, antineoplastic agents
-moxinum	-moxine	-moxine	monoamine oxidase inhibitors
-mycinum	-mycin-	-mycine	antibiotics, produced by *Streptomyces* strains
nifur-	nifur-	nifur-	5-nitrofuran derivatives
-orexum	-orex	-orex	anorexigenic agents
-praminum	-pramine	-pramine	dibenzazepine, compounds of the imipramine type
-quinum	-quine	-quine	quinoline derivatives
-serpinum	-serpine	-serpine	derivatives of *Rauwolfia* alkaloids
-stigminum	-stigmine	-stigmine	anticholinesterases
sulfa-	sulfa-	sulfa-	sulfonamides, used as antimicrobials
-tizidum	-tizide	-tizide	diuretics which are thiazide derivatives
-toinum	-toin	-toïne	antiepileptics which are hydantoin derivatives
-verinum	-verine	-vérine	spasmolytics with a papaverine-like action
-inum	-ine	-ine	alkaloids and organic bases
-onum	-one	-one	ketones
-onium	-onium	-onium	quaternary amines
